Wedbush Reiterates Outperform on Day One Biopharmaceutical, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintained a $38 price target.
September 12, 2023 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst maintains Outperform rating and $38 price target on Day One Biopharmaceutical.
The reiteration of an Outperform rating by a reputable analyst like Robert Driscoll from Wedbush is a positive signal for the stock. The maintained price target of $38 also indicates confidence in the company's future performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100